# Courtney Miller

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/courtney-miller
Canonical HTML page: https://getbiobrief.com/entity/courtney-miller

## Timeline

- **2026-Q3 (estimated)**: Clinical Milestones — Anticipated updates on Phase 1/2 trial progress for MT-125 in GBM.
- **2026-03-24**: BioFlorida Showcase — Presentation in the Cornerstone Session: Innovation at BioFlorida.
- **2026-03-10**: Investival Showcase — Participation in the South Florida - The Rising Life Science Hub event.
- **2026-03-09**: Conference Announcement — Invited to present at two major South Florida life sciences events.
- **2026-02-15**: Partnering Circuit — Presented at BioCom California Global Life Science Partnering Conference.

## Recent coverage (1 stories)

### Myosin Therapeutics to Detail Mechanical Oncology Strategy at Florida Summits
2026-03-10 01:08:18 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Myosin Therapeutics is set to present its first-in-class NMIIA/IIB inhibitor, MT-125, at two major South Florida life sciences conferences this March. The company's unique approach targets the physical mechanics of glioblastoma cells, offering a potential solution to traditional drug resistance.
Full story: https://getbiobrief.com/story/myosin-therapeutics-mt125-glioblastoma-conferences

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.